RT Journal Article
T1 Anticoagulation Therapy in Patients With Coronavirus Disease 2019: Results From a Multicenter International Prospective Registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019 [HOPE-COVID19]).
A1 Santoro, Francesco
A1 Núñez-Gil, Ivan J
A1 Viana-Llamas, María C
A1 Maroun Eid, Charbel
A1 Romero, Rodolfo
A1 Fernández Rozas, Inmaculada
A1 Aparisi, Alvaro
A1 Becerra-Muñoz, Victor Manuel
A1 García Aguado, Marcos
A1 Huang, Jia
A1 Maltese, Ludovica
A1 Cerrato, Enrico
A1 Alfonso-Rodriguez, Emilio
A1 Castro Mejía, Alex Fernando
A1 Marin, Francisco
A1 Raposeiras Roubin, Sergio
A1 Pepe, Martino
A1 Moreno Munguia, Victor H
A1 Feltes, Gisela
A1 Navas, Jesus Varas
A1 Cortese, Bernardo
A1 Buzón, Luis
A1 Liebetrau, Cristoph
A1 Ramos-Martinez, Raquel
A1 Fernandez-Ortiz, Antonio
A1 Estrada, Vicente
A1 Brunetti, Natale Daniele
AB No standard therapy, including anticoagulation regimens, is currently recommended for coronavirus disease 2019. Aim of this study was to evaluate the efficacy of anticoagulation in coronavirus disease 2019 hospitalized patients and its impact on survival. Multicenter international prospective registry (Health Outcome Predictive Evaluation for Corona Virus Disease 2019). Hospitalized patients with coronavirus disease 2019. Five thousand eight hundred thirty-eight consecutive coronavirus disease 2019 patients. Anticoagulation therapy, including prophylactic and therapeutic regimens, was obtained for each patient. Five thousand four hundred eighty patients (94%) did not receive any anticoagulation before hospitalization. Two-thousand six-hundred one patients (44%) during hospitalization received anticoagulation therapy and it was not associated with better survival rate (81% vs 81%; p = 0.94) but with higher risk of bleeding (2.7% vs 1.8%; p = 0.03). Among patients admitted with respiratory failure (49%, n = 2,859, including 391 and 583 patients requiring invasive and noninvasive ventilation, respectively), anticoagulation started during hospitalization was associated with lower mortality rates (32% vs 42%; p  Anticoagulation therapy in general population with coronavirus disease 2019 was not associated with better survival rates but with higher bleeding risk. Better results were observed in patients admitted with respiratory failure and requiring invasive ventilation.
YR 2021
FD 2021
LK http://hdl.handle.net/10668/17589
UL http://hdl.handle.net/10668/17589
LA en
DS RISalud
RD Apr 9, 2025